- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 22 patient starts across both programs to date –
- Ended quarter with $227M in cash, cash equivalents, marketable securities and.
Diamonds Manufactured 2023 imparcialoaxaca.mx - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from imparcialoaxaca.mx Daily Mail and Mail on Sunday newspapers.
Oral presentation details efficacy, safety and health-related quality of life data in adult and pediatric patients with sickle cell disease treated with lovo-cel in HGB-206 Group C and HGB-210 .